Novo Nordisk background on obesity drugs, shares watched by global investors
28.06.2026 - 14:09:52 | ad-hoc-news.de
By Christina Vogel, Background & Management desk. Reviewed prior to publication on 2026-06-28, 14:09.
Novo Nordisk (DK0062498333) continues to draw strong attention from international investors thanks to its leadership in obesity and diabetes treatments, with shares listed on Nasdaq Copenhagen and a large American Depositary Receipt program on the New York Stock Exchange.Novo Nordisk investor share information
Regulatory and reimbursement backdrop
As a global leader in GLP-1 medicines, Novo Nordisk faces ongoing regulatory review and reimbursement debates in major markets including the United States and the European Union, where payers are assessing long-term cost effectiveness of obesity drugs.Reuters coverage of obesity drug reimbursement
Health technology assessment bodies such as the UK National Institute for Health and Care Excellence and various US insurers continue to publish guidance on coverage criteria for therapies like Wegovy, directly influencing prescription volumes and revenue visibility for Novo Nordisk.NICE guidance on semaglutide for weight management
Competitive landscape and analyst focus
In the competitive obesity and diabetes space, Novo Nordisk faces increasing rivalry from Eli Lilly, whose tirzepatide-based treatments have rapidly gained market share, creating a dual-pillar market in GLP-1 and GIP/GLP-1 agonists.Financial Times analysis of GLP-1 competition
Analysts from major houses such as Goldman Sachs and JPMorgan regularly update their views on Novo Nordisk, often highlighting pipeline developments, capacity expansion plans and potential cardiovascular outcome benefits as key drivers for the stock.Goldman Sachs research on obesity drugs
Further news and data on the Novo Nordisk shares
Background pieces, regulatory updates and analyst views on Novo Nordisk are collected on our topic page and the company's Investor Relations hub.
The product behind the stock
Wegovy, Novo Nordisk's once-weekly semaglutide injection for weight management, is one of the company's flagship obesity medicines and has significantly increased global awareness of pharmaceutical approaches to treating obesity.
The listing in brief
Novo Nordisk shares last traded at a recent price observed around their Nasdaq Copenhagen listing in Danish kroner; investors also follow the company's American Depositary Receipts on the New York Stock Exchange.
Novo Nordisk at a glance
- Company: Novo Nordisk A/S
- ISIN: DK0062498333
- WKN: A3ETZP
- Ticker: NOVO-B
- Trading venue: Nasdaq Copenhagen
- Price (as of 2026-06-26, 16:00): 930.00 DKK
- Market cap: 2.10 trillion DKK (as of 2026-06-26)
- Sector / industry: Pharmaceuticals - Biotechnology and life sciences
- Index membership: OMX Copenhagen 25, Stoxx Europe 600
- Next earnings date: not officially scheduled
This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.
